SAFETY DATA SHEET

Ivermectin (3.5%) Formulation

Version: 2.1  Revision Date: 23.03.2020  SDS Number: 4698083-00003  Date of last issue: 19.08.2019
Date of first issue: 29.07.2019

1. PRODUCT AND COMPANY IDENTIFICATION

Product name: Ivermectin (3.5%) Formulation

Manufacturer or supplier’s details
Company: MSD
Address: 50 Tuas West Drive
Singapore  -  Singapore  638408
Telephone: 908-740-4000
Emergency telephone number: 65 6697 2111 (24/7/365)
E-mail address: EHSDATASTEWARD@msd.com
Telefax: 908-735-1496

Recommended use of the chemical and restrictions on use
Recommended use: Veterinary product

2. HAZARDS IDENTIFICATION

GHS Classification
Acute toxicity (Oral): Category 4
Specific target organ toxicity - single exposure (Oral): Category 2 (Central nervous system)
Specific target organ toxicity - repeated exposure (Oral): Category 2 (Central nervous system)
Short-term (acute) aquatic hazard: Category 1
Long-term (chronic) aquatic hazard: Category 1

GHS label elements
Hazard pictograms: ❐ ❐ ❐
Signal word: Warning
Hazard statements: H302 Harmful if swallowed.
H371 May cause damage to organs (Central nervous system) if swallowed.
H373 May cause damage to organs (Central nervous system) through prolonged or repeated exposure if swallowed.
H410 Very toxic to aquatic life with long lasting effects.

Precautionary statements:

Prevention:
- P260 Do not breathe mist or vapours.
- P264 Wash skin thoroughly after handling.
- P270 Do not eat, drink or smoke when using this product.
- P273 Avoid release to the environment.

Response:
- P301 + P312 + P330 IF SWALLOWED: Call a POISON CENTER/ doctor if you feel unwell. Rinse mouth.
- P308 + P311 IF exposed or concerned: Call a POISON CENTER/ doctor.
- P391 Collect spillage.

Storage:
- P405 Store locked up.

Disposal:
- P501 Dispose of contents/ container to an approved waste disposal plant.

Additional Labelling:
The following percentage of the mixture consists of ingredient(s) with unknown hazards to the aquatic environment: 1.42 %

Other hazards which do not result in classification:
None known.

3. COMPOSITION/INFORMATION ON INGREDIENTS

<table>
<thead>
<tr>
<th>Substance / Mixture</th>
<th>Components</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>Chemical name</th>
<th>CAS-No.</th>
<th>Concentration (% w/w)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ivermectin</td>
<td>70288-86-7</td>
<td>&gt;= 2.5 - &lt; 10</td>
</tr>
<tr>
<td>Aluminum tristearate</td>
<td>637-12-7</td>
<td>&gt;= 1 - &lt; 10</td>
</tr>
<tr>
<td>2,6-Di-tert-butyl-p-cresol</td>
<td>128-37-0</td>
<td>&gt;= 0.25 - &lt; 1</td>
</tr>
</tbody>
</table>

4. FIRST AID MEASURES

General advice: In the case of accident or if you feel unwell, seek medical advice immediately. When symptoms persist or in all cases of doubt seek medical advice.

If inhaled: If inhaled, remove to fresh air. Get medical attention if symptoms occur.

In case of skin contact: Wash with water and soap as a precaution. Get medical attention if symptoms occur.

In case of eye contact: Flush eyes with water as a precaution. Get medical attention if irritation develops and persists.

If swallowed: If swallowed, DO NOT induce vomiting unless directed to do so by medical personnel.
Ivermectin (3.5%) Formulation

5. FIREFIGHTING MEASURES

Suitable extinguishing media : Water spray
Alcohol-resistant foam
Carbon dioxide (CO2)
Dry chemical

Unsuitable extinguishing media : None known.

Specific hazards during firefighting : Exposure to combustion products may be a hazard to health.

Hazardous combustion products : Carbon oxides
Metal oxides

Specific extinguishing methods : Use extinguishing measures that are appropriate to local circumstances and the surrounding environment.
Use water spray to cool unopened containers.
Remove undamaged containers from fire area if it is safe to do so.
Evacuate area.

Special protective equipment for firefighters : In the event of fire, wear self-contained breathing apparatus. Use personal protective equipment.

6. ACCIDENTAL RELEASE MEASURES

Personal precautions, protective equipment and emergency procedures : Use personal protective equipment.
Follow safe handling advice and personal protective equipment recommendations.

Environmental precautions : Discharge into the environment must be avoided.
Prevent further leakage or spillage if safe to do so.
Prevent spreading over a wide area (e.g. by containment or oil barriers).
Retain and dispose of contaminated wash water.
Local authorities should be advised if significant spillages cannot be contained.

Methods and materials for containment and cleaning up : Soak up with inert absorbent material.
For large spills, provide dyeing or other appropriate containment to keep material from spreading. If dyed material can be pumped, store recovered material in appropriate container.
Clean up remaining materials from spill with suitable absorbent.
Local or national regulations may apply to releases and dis-
posal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable. Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

7. HANDLING AND STORAGE

Technical measures: See Engineering measures under EXPOSURE CONTROLS/PERSONAL PROTECTION section.

Local/Total ventilation: Use only with adequate ventilation.

Advice on safe handling: Avoid inhalation of vapour or mist.
Do not swallow.
Avoid contact with eyes.
Avoid prolonged or repeated contact with skin.
Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment.
Take care to prevent spills, waste and minimize release to the environment.

Conditions for safe storage: Keep in properly labelled containers.
Store locked up.
Store in accordance with the particular national regulations.

Materials to avoid: Do not store with the following product types:
Strong oxidizing agents

8. EXPOSURE CONTROLS/PERSONAL PROTECTION

Components with workplace control parameters

<table>
<thead>
<tr>
<th>Components</th>
<th>CAS-No.</th>
<th>Value type (Form of exposure)</th>
<th>Control parameters / Permissible concentration</th>
<th>Basis</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ivermectin</td>
<td>70288-86-7</td>
<td>TWA</td>
<td>0.05 mg/m³ (OEB 3)</td>
<td>Internal</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Further information: Skin</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Wipe limit</td>
<td></td>
<td>0.5 mg/100 cm²</td>
<td>Internal</td>
<td></td>
</tr>
<tr>
<td>Aluminum tristearate</td>
<td>637-12-7</td>
<td>PEL (long term)</td>
<td>10 mg/m³</td>
<td>SG OEL</td>
</tr>
<tr>
<td></td>
<td></td>
<td>TWA (Respirable particulate matter)</td>
<td>1 mg/m³ (Aluminium)</td>
<td>ACGIH</td>
</tr>
<tr>
<td></td>
<td></td>
<td>TWA (Inhalable particulate matter)</td>
<td>10 mg/m³</td>
<td>ACGIH</td>
</tr>
<tr>
<td></td>
<td></td>
<td>TWA (Respirable particulate matter)</td>
<td>3 mg/m³</td>
<td>ACGIH</td>
</tr>
<tr>
<td>2,6-Di-tert-butyl-p-cresol</td>
<td>128-37-0</td>
<td>PEL (long term)</td>
<td>10 mg/m³</td>
<td>SG OEL</td>
</tr>
<tr>
<td></td>
<td></td>
<td>TWA (Inhalable particulate matter)</td>
<td>2 mg/m³</td>
<td>ACGIH</td>
</tr>
</tbody>
</table>
Engineering measures:

Use appropriate engineering controls and manufacturing technologies to control airborne concentrations (e.g., dripless quick connections). All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment. Containment technologies suitable for controlling compounds are required to control at source and to prevent migration of the compound to uncontrolled areas (e.g., open-face containment devices). Minimize open handling.

Personal protective equipment:

Respiratory protection:
If adequate local exhaust ventilation is not available or exposure assessment demonstrates exposures outside the recommended guidelines, use respiratory protection.

Filter type:
Combined particulates and organic vapour type

Hand protection:
Material: Chemical-resistant gloves
Remarks: Consider double gloving.

Eye protection:
Wear safety glasses with side shields or goggles.
If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles.
Wear a face shield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols.

Skin and body protection:
Work uniform or laboratory coat.
Additional body garments should be used based upon the task being performed (e.g., sleevelets, apron, gauntlets, disposable suits) to avoid exposed skin surfaces.
Use appropriate degowning techniques to remove potentially contaminated clothing.

Hygiene measures:
If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place.
When using do not eat, drink or smoke.
Wash contaminated clothing before re-use.
The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls.

9. PHYSICAL AND CHEMICAL PROPERTIES

Appearance: gel
Colour: off-white
Odour: characteristic
**SAFETY DATA SHEET**

**Ivermectin (3.5%) Formulation**

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Odour Threshold</td>
<td>No data available</td>
</tr>
<tr>
<td>pH</td>
<td>No data available</td>
</tr>
<tr>
<td>Melting point/freezing point</td>
<td>No data available</td>
</tr>
<tr>
<td>Initial boiling point and boiling range</td>
<td>170 °C</td>
</tr>
<tr>
<td>Flash point</td>
<td>237.2 °C</td>
</tr>
<tr>
<td>Evaporation rate</td>
<td>No data available</td>
</tr>
<tr>
<td>Flammability (solid, gas)</td>
<td>Not applicable</td>
</tr>
<tr>
<td>Flammability (liquids)</td>
<td>Not applicable</td>
</tr>
<tr>
<td>Upper explosion limit / Upper flammability limit</td>
<td>No data available</td>
</tr>
<tr>
<td>Lower explosion limit / Lower flammability limit</td>
<td>No data available</td>
</tr>
<tr>
<td>Vapour pressure</td>
<td>No data available</td>
</tr>
<tr>
<td>Relative vapour density</td>
<td>No data available</td>
</tr>
<tr>
<td>Relative density</td>
<td>0.93 - 0.95</td>
</tr>
<tr>
<td>Density</td>
<td>No data available</td>
</tr>
<tr>
<td>Solubility(ies)</td>
<td>ly practically insoluble</td>
</tr>
<tr>
<td>Water solubility</td>
<td></td>
</tr>
<tr>
<td>Partition coefficient: n-octanol/water</td>
<td>Not applicable</td>
</tr>
<tr>
<td>Auto-ignition temperature</td>
<td>No data available</td>
</tr>
<tr>
<td>Decomposition temperature</td>
<td>No data available</td>
</tr>
<tr>
<td>Viscosity</td>
<td></td>
</tr>
<tr>
<td>Viscosity, dynamic</td>
<td>382 - 384 mPa.s (25 °C)</td>
</tr>
<tr>
<td>Viscosity, kinematic</td>
<td>No data available</td>
</tr>
<tr>
<td>Explosive properties</td>
<td>Not explosive</td>
</tr>
<tr>
<td>Oxidizing properties</td>
<td>The substance or mixture is not classified as oxidizing.</td>
</tr>
<tr>
<td>Molecular weight</td>
<td>No data available</td>
</tr>
<tr>
<td>Particle size</td>
<td>No data available</td>
</tr>
</tbody>
</table>
10. STABILITY AND REACTIVITY

Reactivity: Not classified as a reactivity hazard.
Chemical stability: Stable under normal conditions.
Possibility of hazardous reactions: Can react with strong oxidizing agents.
Conditions to avoid: None known.
Incompatible materials: Oxidizing agents
Hazardous decomposition products: No hazardous decomposition products are known.

11. TOXICOLOGICAL INFORMATION

Information on likely routes of exposure:
Inhalation
Skin contact
Ingestion
Eye contact

Acute toxicity
Harmful if swallowed.

Product:
Acute oral toxicity: Acute toxicity estimate: 1,511 mg/kg
Method: Calculation method

Acute dermal toxicity: Acute toxicity estimate: > 2,000 mg/kg
Method: Calculation method

Components:

Ivermectin:
Acute oral toxicity: LD50 (Rat): 50 mg/kg
LD50 (Mouse): 25 mg/kg
LD50 (Monkey): > 24 mg/kg
Target Organs: Central nervous system
Symptoms: Vomiting, Dilatation of the pupil
Remarks: No mortality observed at this dose.

Acute inhalation toxicity: LC50 (Rat): 5.11 mg/l
Exposure time: 1 h
Test atmosphere: dust/mist

Acute dermal toxicity: LD50 (Rabbit): 406 mg/kg
LD50 (Rat): > 660 mg/kg

Aluminum tristearate:
Acute oral toxicity: LD50 (Rat, female): > 2,000 mg/kg
Remarks: Based on data from similar materials

Acute inhalation toxicity: LC50 (Rat): > 5.15 mg/l
**Exposure time:** 4 h  
**Test atmosphere:** dust/mist  
**Method:** OECD Test Guideline 403  
**Remarks:** Based on data from similar materials

### 2,6-Di-tert-butyl-p-cresol:

<table>
<thead>
<tr>
<th>Test Type</th>
<th>Value</th>
<th>Method</th>
</tr>
</thead>
<tbody>
<tr>
<td>Acute oral toxicity</td>
<td>LD50 (Rat): &gt; 6,000 mg/kg</td>
<td>OECD Test Guideline 401</td>
</tr>
<tr>
<td>Acute dermal toxicity</td>
<td>LD50 (Rat): &gt; 2,000 mg/kg</td>
<td>OECD Test Guideline 402</td>
</tr>
</tbody>
</table>

**Assessment:** The substance or mixture has no acute dermal toxicity

**Skin corrosion/irritation**

Not classified based on available information.

### Components:

**Ivermectin:**

<table>
<thead>
<tr>
<th>Species</th>
<th>Result</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rabbit</td>
<td>No skin irritation</td>
</tr>
</tbody>
</table>

**Aluminum tristearate:**

<table>
<thead>
<tr>
<th>Method</th>
<th>Result</th>
</tr>
</thead>
<tbody>
<tr>
<td>OECD Test Guideline 439</td>
<td>No skin irritation</td>
</tr>
</tbody>
</table>

**Remarks:** Based on data from similar materials

### 2,6-Di-tert-butyl-p-cresol:

<table>
<thead>
<tr>
<th>Species</th>
<th>Result</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rabbit</td>
<td>Mild eye irritation</td>
</tr>
</tbody>
</table>

**Aluminum tristearate:**

<table>
<thead>
<tr>
<th>Method</th>
<th>Result</th>
</tr>
</thead>
<tbody>
<tr>
<td>OECD Test Guideline 405</td>
<td>No eye irritation</td>
</tr>
</tbody>
</table>

**Remarks:** Based on data from similar materials

### Serious eye damage/eye irritation

Not classified based on available information.

### Components:

**Ivermectin:**

<table>
<thead>
<tr>
<th>Species</th>
<th>Result</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rabbit</td>
<td>No skin irritation</td>
</tr>
</tbody>
</table>

**Aluminum tristearate:**

<table>
<thead>
<tr>
<th>Method</th>
<th>Result</th>
</tr>
</thead>
<tbody>
<tr>
<td>OECD Test Guideline 405</td>
<td>No eye irritation</td>
</tr>
</tbody>
</table>

**Remarks:** Based on data from similar materials

### 2,6-Di-tert-butyl-p-cresol:

<table>
<thead>
<tr>
<th>Species</th>
<th>Result</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rabbit</td>
<td>No skin irritation</td>
</tr>
</tbody>
</table>

**Aluminum tristearate:**

<table>
<thead>
<tr>
<th>Method</th>
<th>Result</th>
</tr>
</thead>
<tbody>
<tr>
<td>OECD Test Guideline 405</td>
<td>No eye irritation</td>
</tr>
</tbody>
</table>

**Remarks:** Based on data from similar materials
### Result

- **No eye irritation**

### Method

- OECD Test Guideline 405

### Remarks

- Based on data from similar materials

### Respiratory or skin sensitisation

**Skin sensitisation**

Not classified based on available information.

**Respiratory sensitisation**

Not classified based on available information.

### Components:

**Ivermectin**:

<table>
<thead>
<tr>
<th>Exposure routes</th>
<th>Species</th>
<th>Result</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dermal</td>
<td>Humans</td>
<td>Does not cause skin sensitisation.</td>
</tr>
</tbody>
</table>

**Aluminum tristearate**:

<table>
<thead>
<tr>
<th>Test Type</th>
<th>Exposure routes</th>
<th>Species</th>
<th>Result</th>
<th>Remarks</th>
</tr>
</thead>
<tbody>
<tr>
<td>Local lymph node assay (LLNA)</td>
<td>Skin contact</td>
<td>Mouse</td>
<td>negative</td>
<td>Based on data from similar materials</td>
</tr>
</tbody>
</table>

**2,6-Di-tert-butyl-p-cresol**:

<table>
<thead>
<tr>
<th>Test Type</th>
<th>Exposure routes</th>
<th>Species</th>
<th>Result</th>
</tr>
</thead>
<tbody>
<tr>
<td>Human repeat insult patch test (HRIPT)</td>
<td>Skin contact</td>
<td>Humans</td>
<td>negative</td>
</tr>
</tbody>
</table>

### Germ cell mutagenicity

Not classified based on available information.

### Components:

**Ivermectin**:

<table>
<thead>
<tr>
<th>Genotoxicity in vitro</th>
<th>Test Type</th>
<th>Result</th>
</tr>
</thead>
<tbody>
<tr>
<td>Test Type: Bacterial reverse mutation assay (AMES)</td>
<td>negative</td>
<td></td>
</tr>
<tr>
<td>Test Type: DNA damage and repair, unscheduled DNA synthesis in mammalian cells (in vitro)</td>
<td>Test system: human diploid fibroblasts</td>
<td>negative</td>
</tr>
<tr>
<td>Test Type: Mouse Lymphoma</td>
<td>Result: negative</td>
<td></td>
</tr>
</tbody>
</table>

**Aluminum tristearate**:

<table>
<thead>
<tr>
<th>Genotoxicity in vitro</th>
<th>Test Type</th>
<th>Method</th>
</tr>
</thead>
<tbody>
<tr>
<td>In vitro mammalian cell gene mutation test</td>
<td>OECD Test Guideline 476</td>
<td></td>
</tr>
</tbody>
</table>
Ivermectin (3.5%) Formulation

Genotoxicity in vivo:
- Test Type: Mammalian erythrocyte micronucleus test (in vivo cytogenetic assay)
  - Species: Rat
  - Application Route: Ingestion
  - Method: OECD Test Guideline 474
  - Result: negative
  - Remarks: Based on data from similar materials

2,6-Di-tert-butyl-p-cresol:
- Genotoxicity in vitro:
  - Test Type: Bacterial reverse mutation assay (AMES)
    - Result: negative
  - Test Type: In vitro mammalian cell gene mutation test
    - Result: negative
  - Test Type: Chromosome aberration test in vitro
    - Result: negative

Genotoxicity in vivo:
- Test Type: Mutagenicity (in vivo mammalian bone-marrow cytogenetic test, chromosomal analysis)
  - Species: Rat
  - Application Route: Ingestion
  - Result: negative
  - Remarks: Based on data from similar materials

Carcinogenicity
Not classified based on available information.

Components:

Ivermectin:
- Species: Rat
- Application Route: Oral
- NOAEL: 1.5 mg/kg body weight
- Result: negative
- Remarks: Based on data from similar materials

Species:
- Species: Mouse
- Application Route: Oral
- NOAEL: 2.0 mg/kg body weight
- Result: negative
- Remarks: Based on data from similar materials

2,6-Di-tert-butyl-p-cresol:
- Species: Rat
- Application Route: Ingestion
Reproductive toxicity
Not classified based on available information.

Components:

Ivermectin:
Effects on fertility: Test Type: Fertility
Species: Rat
Application Route: Oral
Fertility: NOAEL: 0.6 mg/kg body weight
Result: Animal testing did not show any effects on fertility.

Effects on foetal development:
Species: Mouse
Application Route: Oral
Developmental Toxicity: NOAEL: 0.2 mg/kg body weight
Result: Teratogenic effects, Embryotoxic effects and adverse effects on the offspring were detected only at high maternally toxic doses

Test Type: Development
Species: Rat
Application Route: Oral
Developmental Toxicity: LOAEL: 0.4 mg/kg body weight
Result: Embryotoxic effects and adverse effects on the offspring were detected.
Remarks: The mechanism or mode of action may not be relevant in humans.

Test Type: Development
Species: Rabbit
Application Route: Oral
Result: Teratogenic effects, Embryotoxic effects and adverse effects on the offspring were detected only at high maternally toxic doses

Aluminum tristearate:
Effects on fertility: Test Type: Two-generation reproduction toxicity study
Species: Rat
Application Route: Ingestion
Method: OECD Test Guideline 416
Result: negative
Remarks: Based on data from similar materials

Effects on foetal development:
Species: Rat
Application Route: Ingestion
Result: negative
Remarks: Based on data from similar materials

2,6-Di-tert-butyl-p-cresol:
**SAFETY DATA SHEET**

**Ivermectin (3.5%) Formulation**

<table>
<thead>
<tr>
<th>Version</th>
<th>Revision Date</th>
<th>SDS Number</th>
<th>Date of last issue</th>
<th>Date of first issue</th>
</tr>
</thead>
<tbody>
<tr>
<td>2.1</td>
<td>23.03.2020</td>
<td>4698083-00003</td>
<td>19.08.2019</td>
<td>29.07.2019</td>
</tr>
</tbody>
</table>

**Effects on fertility**
- Test Type: Two-generation reproduction toxicity study
- Species: Rat
- Application Route: Ingestion
- Result: negative

**Effects on foetal development**
- Test Type: Embryo-foetal development
- Species: Rat
- Application Route: Ingestion
- Result: negative

**STOT - single exposure**
May cause damage to organs (Central nervous system) if swallowed.

**Components:**

**Ivermectin:**
- Target Organs: Central nervous system
- Assessment: Causes damage to organs.

**STOT - repeated exposure**
May cause damage to organs (Central nervous system) through prolonged or repeated exposure if swallowed.

**Components:**

**Ivermectin:**
- Target Organs: Central nervous system
- Assessment: Causes damage to organs through prolonged or repeated exposure.

**2,6-Di-tert-butyl-p-cresol:**
- Assessment: No significant health effects observed in animals at concentrations of 100 mg/kg bw or less.

**Repeated dose toxicity**

**Components:**

**Ivermectin:**
- Species: Dog
- NOAEL: 0.5 mg/kg
- LOAEL: 1 mg/kg
- Application Route: Oral
- Exposure time: 14 Weeks
- Target Organs: Central nervous system
- Symptoms: Dilatation of the pupil, Tremors, Lack of coordination, anorexia

- Species: Monkey
- NOAEL: 1.2 mg/kg
- Application Route: Oral
- Exposure time: 2 Weeks
- Remarks: No significant adverse effects were reported
SAFETY DATA SHEET

Ivermectin (3.5%) Formulation

<table>
<thead>
<tr>
<th>Version</th>
<th>Revision Date:</th>
<th>SDS Number:</th>
<th>Date of last issue:</th>
<th>Date of first issue:</th>
</tr>
</thead>
<tbody>
<tr>
<td>2.1</td>
<td>23.03.2020</td>
<td>4698083-00003</td>
<td>19.08.2019</td>
<td>29.07.2019</td>
</tr>
</tbody>
</table>

Species: Rat
NOAEL: 0.4 mg/kg
LOAEL: 0.8 mg/kg
Application Route: Oral
Exposure time: 3 Months
Target Organs: spleen, Bone marrow, Kidney

**Aluminum tristearate:**
Species: Rat
NOAEL: >= 5,000 mg/kg
Application Route: Ingestion
Exposure time: 90 Days
Remarks: Based on data from similar materials

**2,6-Di-tert-butyl-p-cresol:**
Species: Rat
NOAEL: 25 mg/kg
Application Route: Ingestion
Exposure time: 22 Months

Aspiration toxicity
Not classified based on available information.

Experience with human exposure

**Components:**

**Ivermectin:**
Skin contact: Remarks: Can be absorbed through skin.
Eye contact: Remarks: May irritate eyes.
Ingestion: Symptoms: Drowsiness, Dilatation of the pupil, Tremors, Vomiting, anorexia, Lack of coordination

12. ECOLOGICAL INFORMATION

Ecotoxicity

**Components:**

**Ivermectin:**
Toxicity to fish: LC50 (Oncorhynchus mykiss (rainbow trout)): 0.003 mg/l Exposure time: 96 h
LC50 (Lepomis macrochirus (Bluegill sunfish)): 0.0048 mg/l Exposure time: 96 h
Toxicity to daphnia and other aquatic invertebrates: EC50 (Daphnia magna (Water flea)): 0.000025 mg/l Exposure time: 48 h
Toxicity to algae/aquatic plants: EC50 (Pseudokirchneriella subcapitata (green algae)): > 9.1 mg/l Exposure time: 72 h Method: OECD Test Guideline 201
SAFETY DATA SHEET

Ivermectin (3.5%) Formulation

Version 2.1
Revision Date: 23.03.2020
SDS Number: 4698083-00003
Date of last issue: 19.08.2019
Date of first issue: 29.07.2019

NOEC (Pseudokirchneriella subcapitata (green algae)): 9.1 mg/l
Exposure time: 72 h
Method: OECD Test Guideline 201

M-Factor (Acute aquatic toxicity): 10,000
M-Factor (Chronic aquatic toxicity): 10,000

Aluminum tristearate:

Ecotoxicology Assessment

Acute aquatic toxicity: Toxic effects cannot be excluded
Chronic aquatic toxicity: Toxic effects cannot be excluded

2,6-Di-tert-butyl-p-cresol:

Toxicity to fish: LC50 (Danio rerio (zebra fish)): > 0.57 mg/l
Exposure time: 96 h

Toxicity to daphnia and other aquatic invertebrates: EC50 (Daphnia magna (Water flea)): 0.48 mg/l
Exposure time: 48 h
Method: OECD Test Guideline 202

Toxicity to algae/aquatic plants: ErC50 (Pseudokirchneriella subcapitata (green algae)): > 0.24 mg/l
Exposure time: 72 h
Method: OECD Test Guideline 201

NOEC (Pseudokirchneriella subcapitata (green algae)): 0.24 mg/l
Exposure time: 72 h
Method: OECD Test Guideline 201

M-Factor (Acute aquatic toxicity): 1
Toxicity to fish (Chronic toxicity): NOEC (Oryzias latipes (Japanese medaka)): 0.053 mg/l
Exposure time: 30 d
Method: OECD Test Guideline 210

Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity):
NOEC (Daphnia magna (Water flea)): 0.316 mg/l
Exposure time: 21 d
M-Factor (Chronic aquatic toxicity): 1

Toxicity to microorganisms:
EC50: > 10,000 mg/l
Exposure time: 3 h
Method: OECD Test Guideline 209
Persistence and degradability

Components:

Ivermectin:
Biodegradability : Result: Not readily biodegradable.
Biodegradation: 50 %
Exposure time: 240 d

2,6-Di-tert-butyl-p-cresol:
Biodegradability : Result: Not readily biodegradable.
Biodegradation: 4.5 %
Exposure time: 28 d
Method: OECD Test Guideline 301C

Bioaccumulative potential

Components:

Ivermectin:
Bioaccumulation : Bioconcentration factor (BCF): 74
Partition coefficient: n-octanol/water : log Pow: 3.22

2,6-Di-tert-butyl-p-cresol:
Bioaccumulation : Species: Cyprinus carpio (Carp)
Bioconcentration factor (BCF): 330 - 1,800
Partition coefficient: n-octanol/water : log Pow: 5.1

Mobility in soil
No data available

Other adverse effects
No data available

13. DISPOSAL CONSIDERATIONS

Disposal methods
Waste from residues : Dispose of in accordance with local regulations.
Contaminated packaging : Empty containers should be taken to an approved waste handling site for recycling or disposal.
If not otherwise specified: Dispose of as unused product.

14. TRANSPORT INFORMATION

International Regulations

UNRTDG
UN number : UN 3082
Proper shipping name : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, LIQUID, N.O.S.
Class: 9  
Packing group: III  
Labels: Miscellaneous

**IATA-DGR**
- UN/ID No.: UN 3082  
- Proper shipping name: Environmentally hazardous substance, liquid, n.o.s. (Ivermectin)

**IMDG-Code**
- UN number: UN 3082  
- Proper shipping name: ENVIRONMENTALLY HAZARDOUS SUBSTANCE, LIQUID, N.O.S. (Ivermectin)

**Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code**
Not applicable for product as supplied.

**Special precautions for user**
The transport classification(s) provided herein are for informational purposes only, and solely based upon the properties of the unpackaged material as it is described within this Safety Data Sheet. Transportation classifications may vary by mode of transportation, package sizes, and variations in regional or country regulations.

**15. REGULATORY INFORMATION**

Safety, health and environmental regulations/legislation specific for the substance or mixture

**Workplace Safety and Health Act and Workplace Safety and Health (General Provisions) Regulations:** This product is subjected to the SDS, labelling, PEL and other requirements in the Act/Regulations.

- Environmental Protection and Management Act and Environmental Protection and Management (Hazardous Substances) Regulations: Not applicable
- Fire Safety (Petroleum and Flammable Materials) Regulations: Not applicable

The components of this product are reported in the following inventories:
**SAFETY DATA SHEET**

**Ivermectin (3.5%) Formulation**

<table>
<thead>
<tr>
<th>Version</th>
<th>Revision Date</th>
<th>SDS Number</th>
<th>Date of last issue: 19.08.2019</th>
</tr>
</thead>
<tbody>
<tr>
<td>2.1</td>
<td>23.03.2020</td>
<td>4698083-00003</td>
<td>Date of first issue: 29.07.2019</td>
</tr>
</tbody>
</table>

AICS : not determined
DSL : not determined
IECSC : not determined

### 16. OTHER INFORMATION

#### Further information


Date format: dd.mm.yyyy

#### Full text of other abbreviations

ACGIH : USA. ACGIH Threshold Limit Values (TLV)
SG OEL : Singapore. Workplace Safety and Health Act - First Schedule Permissible Exposure Limits of Toxic Substances

ACGIH / TWA : 8-hour, time-weighted average
SG OEL / PEL (long term) : Permissible Exposure Level (PEL) Long Term

AICS - Australian Inventory of Chemical Substances; ANTT - National Agency for Transport by Land of Brazil; ASTM - American Society for the Testing of Materials; bw - Body weight; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; Nch - Chilean Norm; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NOM - Official Mexican Norm; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TDG - Transportation of Dangerous Goods; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative; WHMIS - Workplace Hazardous Materials Information System
The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

SG / EN